Emphysema News and Research

Latest Emphysema News and Research

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

Talecris Biotherapeutics announced today that it has received approval from Health Canada for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more purified and concentrated version of PROLASTIN® produced using advances in manufacturing technology. A similar approval for PROLASTIN-C was granted by the U.S. Food and Drug Administration on October 17, 2009.

17 Feb 2010

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.

9 Feb 2010

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.

5 Feb 2010

Patients with COPD could benefit from treatment with drugs that block sestrin function

Chronic obstructive pulmonary disease (COPD) is defined by emphysema and/or chronic bronchitis. It destroys the normal architecture of the lung and inhibits the mechanical aspects of breathing, which prevents necessary gas exchange. Patients suffer from coughing fits, wheezing, and increased incidence of lung infections.

27 Jan 2010

Elevation Pharmaceuticals closes $30M tranched Series A financing

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing.

21 Jan 2010

Research shows strong links between COPD and heart function

A common lung condition, COPD (chronic obstructive pulmonary disease) diminishes the heart's ability to pump effectively even when the disease has no or mild symptoms, according to research published in the Jan. 21 issue of the New England Journal of Medicine.

21 Jan 2010

One-legged cycling can improve overall fitness in COPD patients

People with chronic-obstructive pulmonary disease (COPD) often find themselves in a downward spiral when it comes to their health. COPD, which includes chronic bronchitis and emphysema, means that the elasticity of the lungs is destroyed.

21 Jan 2010

Study: Heart's ability to pump effectively is diminished among people with common lung disease

A new study from Columbia University Medical Center researchers, has found that the heart's ability to pump effectively is diminished among people with a common lung disease, even in people with no or mild symptoms.

21 Jan 2010

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

18 Jan 2010

Researchers identify ways to predict patients with small-cell lung cancer

Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

18 Jan 2010

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

At least three tumor microRNAs appear to predict when first-line chemotherapy will prove ineffective in some patients with small cell lung cancer, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held Jan. 11-14, 2010.

13 Jan 2010

Childhood ETS may lead to emphysema

Children regularly exposed to tobacco smoke at home were more likely to develop early emphysema in adulthood. This finding by researchers at Columbia University's Mailman School of Public Health suggests that the lungs may not recover completely from the effects of early-life exposures to tobacco smoke (ETS). The study is published in the December 2009 American Journal of Epidemiology.

29 Dec 2009

Double-lung transplant donation saves life

Kurt Penner, who in 2002, was days away from dying of emphysema received a life-saving double-lung transplant through the Trillium Gift of Life Network (TGLN). On December 27, he'll be carrying the 2010 Olympic torch for 300 metres through the streets of Woodstock, Ontario, thanks to that donation.

24 Dec 2009

Thyroid cancer on the rise

As seen on "NBC Nightly News" Monday, December 21, the thyroid cancer rate is rising rapidly, especially among women. The American Thyroid Association's members are working to educate more people about thyroid cancer as well as treat and cure it.

23 Dec 2009

BUSM researchers discover new gene therapy for treating emphysema patients

Researchers from Boston University School of Medicine (BUSM) have discovered a new gene therapy that may prevent the progression of emphysema. The study, which appears on-line in the Journal of Clinical Investigation, describes a method to express therapeutic genes in lung tissue for a lifetime after only a single treatment.

22 Dec 2009

Scientists identify new therapeutic approach for overcoming emphysema

Individuals with single-gene mutations that mean they have abnormally low levels of the protein alpha-1 antitrypsin are highly susceptible to emphysema, a progressive lung disease that causes severe shortness of breath.

22 Dec 2009

Genetic variant associated with reduced risk of COPD

What: Researchers have discovered evidence that suggests a genetic variant may be associated with better preserved lung function among children with asthma and adults who smoke, according to a new study funded by the National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health.

18 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

BUSM Pulmonary Center awarded $1.4M grant to derive stem cells and lung progenitors from lung disease patients

Boston University School of Medicine's (BUSM) Pulmonary Center has received a two-year $1.4 million grant from the National Heart, Lung, and Blood Institute to derive stem cells and lung progenitors from patients with lung disease.

16 Dec 2009

Emphysema News and Research

Latest Emphysema News and Research

Health Canada approves Talecris Biotherapeutics' PROLASTIN-C for AAT deficiency

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Patients with COPD could benefit from treatment with drugs that block sestrin function

Elevation Pharmaceuticals closes $30M tranched Series A financing

Research shows strong links between COPD and heart function

One-legged cycling can improve overall fitness in COPD patients

Study: Heart's ability to pump effectively is diminished among people with common lung disease

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

Researchers identify ways to predict patients with small-cell lung cancer

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

Childhood ETS may lead to emphysema

Double-lung transplant donation saves life

Thyroid cancer on the rise

BUSM researchers discover new gene therapy for treating emphysema patients

Scientists identify new therapeutic approach for overcoming emphysema

Genetic variant associated with reduced risk of COPD

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

BUSM Pulmonary Center awarded $1.4M grant to derive stem cells and lung progenitors from lung disease patients

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Emphysema News and Research

Latest Emphysema News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in